How to fund a biotech startup in Europe: the guide

Three sources of capital, one strategic question

European biotech funding comes from three structurally different sources, each with a different logic, a different timeline, and a different set of requirements. Understanding how they interact is more important than understanding any one of them individually.

Public non-dilutive capital, primarily grants from the European Innovation Council and national programmes, funds specific research and innovation activities in exchange for deliverables and reporting obligations. It does not require equity, does not impose governance obligations, and does not constrain the company's strategic direction. For early-stage assets, it is almost always the right capital source to engage first.

Venture capital funds a company's development in exchange for equity and governance rights. It imposes milestone obligations, reporting requirements, and eventually exit pressure. It is expensive in dilution terms and comes with strings that persist for the life of the investment. It is also, for assets that have crossed the Valley of Death and demonstrated credible clinical potential, the most powerful source of scale capital available.

Pharma partnerships, whether in-licensing agreements, co-development deals, or corporate venture investments, represent a third path that most early-stage founders underestimate. In European biotech, the most probable commercial outcome for a significant proportion of assets is not an IPO but a pharma transaction. Planning for that exit from day one changes which data gets generated, in what sequence, and for whom.

Why public grants come first

The logic for prioritising non-dilutive capital before equity is simple and compounding. A startup that uses a 500,000 euro regional grant to complete IND-enabling studies arrives at a Series A conversation with a materially different asset than one that has used Series A capital for the same purpose. The data is the same. The investor's perspective on it is not. In the first case, the company has demonstrated capital efficiency and de-risked the asset using public money. In the second case, the VC has paid for work that could have been done without dilution.

The EIC Accelerator is the most significant non-dilutive instrument available to European biotech startups. It offers grants of up to 2.5 million euros for innovation and scale-up activities, with an optional equity component of up to 15 million euros for the most competitive applicants. Acceptance rates in life sciences run at approximately 3 to 5 percent in competitive rounds. The barrier is high. The reward, for companies that clear it, is both the capital and the signal: an EIC grant is a credible validation of commercial potential that European VCs recognise and respect.

Below the EIC, a well-structured non-dilutive strategy layers national and regional instruments. In Italy, MIMIT innovation vouchers, Regione Lombardia life sciences calls, and PNRR allocations all provide capital at specific development stages. In Germany, BMBF programmes cover translational research. In France, Bpifrance innovation grants serve similar functions. Each instrument has its own eligibility criteria, timeline, and reporting obligations. Mapping them before opening the cap table is not optional planning. It is the difference between arriving at a VC conversation with leverage and arriving without it.

When venture capital becomes the right instrument

The transition from grant-funded to equity-funded development is not a milestone to be reached as quickly as possible. It is a threshold to be crossed at the right moment, which is when the asset has accumulated enough public-capital-funded de-risking to command a defensible pre-money valuation.

European life sciences VCs evaluate early-stage assets against a specific set of criteria that differ from their US counterparts in important ways. The average Series A in European biotech runs at approximately 18 to 22 million euros, compared to 40 to 60 million dollars in the US. Smaller tickets mean higher selectivity and more rigorous pre-investment requirements. A European VC committing 15 million euros to a preclinical asset is proportionally more exposed than a US fund writing a 40 million dollar check at the same stage.

What European institutional VCs require before a Series A conversation is productive:

• A milestone map built around value inflection points, not research activities. Each milestone should move the pre-money valuation by a describable amount and bring the asset closer to the exit scenario.
• A specific and credible exit scenario, naming the pharma companies that would consider acquiring or licensing the asset, their strategic rationale, and the evidence package that would make a transaction financially rational for them.
• A capital ask framed as probability purchased, not budget spent. Every euro in the use-of-funds slide should trace to a specific risk-reduction event.
• A non-dilutive capital track record, demonstrating that the team can access and deploy public capital efficiently. An EIC grant or a well-managed national programme tells a VC something useful about operational competence.

Founders who arrive at Series A conversations without this architecture consistently underperform relative to those who have built it. The science may be equivalent. The investor's ability to evaluate it is not.

Pharma as capital source, not just as exit

Corporate venture capital arms of pharmaceutical companies represent a distinct capital category that most early-stage founders either overlook or approach incorrectly. Novartis Venture Fund, Pfizer Ventures, Roche Venture Fund, and Johnson and Johnson Innovation all have active European programmes. They invest differently from financial VCs: strategic fit matters as much as financial return, and a CVC investment from the right pharma company opens business development conversations that no financial intermediary can replicate.

The practical implication is that pharma CVCs should appear in the funding strategy from the beginning, not as a last resort when financial VCs have passed. An early conversation with a pharma CVC that does not result in an investment can still generate intelligence about what the pharma company's BD team needs to see at the next inflection point. That intelligence is worth more than most early-stage founders realise when they are structuring their milestone plan.

Non-CVC pharma partnerships, including sponsored research agreements, option agreements, and co-development structures, represent another capital path that is rarely discussed in the context of early-stage funding. A sponsored research agreement with a pharma company funds specific experiments in exchange for an option to license the results. It provides non-dilutive capital, generates data that a pharma company considers credible, and creates a relationship that can evolve into a full licensing deal. For assets in therapeutic areas where a specific pharma company has a clear strategic interest, this path can be more efficient than either grants or equity.

The integrated capital strategy

The most effective European biotech funding strategies are not sequential choices between grants, equity, and pharma. They are integrated architectures in which each capital source is deployed at the stage where it creates the most leverage for the next conversation.

A practical framework for an early-stage Italian or European biotech startup:

• Map the full development path to the most probable exit, identifying the three or four key value inflection points at which the asset becomes worth materially more.
• Match each inflection point to the capital source best suited to fund it: grants for early de-risking, equity for clinical development, pharma capital for assets with clear strategic fit.
• Sequence grant applications and equity rounds to maintain leverage: come to every VC conversation with data already generated, not with a plan to generate it.
• Keep pharma in the picture throughout: every experiment should produce data that is legible to a pharma business development team, not only to a scientific peer reviewer.
• Build the investment architecture before approaching any capital source: the equity story, the milestone map, and the exit scenario should exist before the first investor meeting, not emerge from it.

This architecture is what distinguishes the European biotech founders who close rounds efficiently from those who spend years in fundraising conversations that never convert. The capital exists. The question is always whether the company has done the work to deserve it.

Frequently asked questions